期刊文献+

Ponatinib抑制野生型和T315I突变型BCR-ABL1激酶的分子模拟

Inhibition of Ponatinib on wild-type and T315I mutant BCR-ABL1 kinase based on molecular simulation
在线阅读 下载PDF
导出
摘要 药物普纳替尼(Ponatinib)对野生型和T315I突变型BCR-ABL1激酶均有较强抑制作用,然而其抑制机理仍然未知。为了更好地了解Ponatinib与BCR-ABL1激酶的作用机理,本文首先运用分子动力学模拟方法研究Ponatinib对BCR-ABL1激酶构象变化的影响,然后采用MM-PBSA方法计算复合物的结合自由能。结果表明:Ponatinib诱导野生型BCR-ABL1激酶P-loop和铰链区相互靠近,导致野生型激酶结合口袋关闭,有利于激酶与药物结合;而Ponatinib诱导T315I突变型BCR-ABL1激酶P-loop和铰链区相互远离,导致T315I突变型激酶结合口袋打开,对激酶与药物结合不利;Ponatinib与野生型以及T315I突变型BCR-ABL1激酶的结合自由能分别为–58.57 kcal/mol和–43.54kcal/mol,Ponatinib对野生型BCR-ABL1激酶的抑制能力明显强于T315I突变体,与文献报道的实验抑制活性结果一致。研究结果对认识靶点蛋白和抑制剂分子机制以及设计新药有重要意义。 The drug Ponatinib had a strong inhibitory effect on wild-type and T315 I mutant BCR-ABL1 kinase,but its inhibition mechanism was still unknown. To have a better understanding of the interaction mechanism between Ponatinib and BCR-ABL1 kinase,the effect of Ponatinib on the conformational changes of BCR-ABL1 kinase was studied by molecular dynamics simulation at first,and then the binding free energy of complex was calculated by the MM-PBSA method. The results indicated that the P-loop and hinge region of wild-type BCR-ABL1 kinase approached each other induced by Ponatinib,leading to the closure of the binding pocket of wild-type BCR-ABL1 kinase,which would be favorable to the binding of drug. In contrast,the P-loop and hinge region of T315 I mutant BCR-ABL1 kinase move far away from each other induced by Ponatinib,resulting in the opening of the binding pocket of T315 I mutant BCR-ABL1 kinase,which was no advantage for kinase binding with drug. The binding free energy of Ponatinib bound to wild-type and T315 I mutant BCR-ABL1 kinase were –58.57 kcal/mol and –43.54 kcal/mol,respectively. The results showed that the inhibitory ability of Ponatinib on wild-type BCR-ABL1 kinase was significantly stronger than that of T315 I mutant,which was consistent with the experimental inhibition activity reported in the literature.This study provided important understanding of the molecular mechanism of target proteins and inhibitors and the design of a new drug.
作者 陈清 王坚毅
出处 《化工进展》 EI CAS CSCD 北大核心 2018年第2期702-707,共6页 Chemical Industry and Engineering Progress
基金 国家自然科学基金项目(21262004)
关键词 分子模拟 T315I突变 普纳替尼 动力学理论 活性 molecular simulation enzyme T315I mutant Ponatinib kinetic theory reactivity
  • 相关文献

参考文献4

二级参考文献90

  • 1邓兵,杜志云,唐煌,古练权.姜黄素类似物的合成及其清除自由基的研究[J].化学研究与应用,2006,18(9):1124-1126. 被引量:18
  • 2贾光锋.α-淀粉酶抑制剂的制备及检测[J].食品与药品,2007,9(02A):34-36. 被引量:13
  • 3赵凯,许鹏举,谷广烨.3,5-二硝基水杨酸比色法测定还原糖含量的研究[J].食品科技,2008,29(08):534-536.
  • 4CHEN Y, WANG H, KANTARJIAN H, et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma, 2013, 54 (7): 1411- 1417.
  • 5SANTOS FP, KANTARJIAN H, QUINTUS-CARDAMA A, et al. Evolution of therapies for chronic myelogenous leukemia [J]. Cancer J, 2011, 17(6) : 465-476.
  • 6OHANIAN M, CORTES J, KANTARJIAN H, et al. Tyrosine kinase inhibitors in acute and chronic leukemias[J]. Expert Opin Pharmacother, 2012, 13(7): 927-938.
  • 7CORTES J, GOLDMAN JM, HUGHES T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure[J]. J Natl Compr Canc Netw, 2012, 10 Suppl 3: S1-S13.
  • 8SHAH NP. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia[J]. Clin Adv Hematol Oncol, 2011, 9 (12) : 925-926.
  • 9NORMAN RA, TOADER D, FERGUSON AD. Structural approaches to obtain kinase selectivity[J]. Trends Pharmacol Sci, 2012, 33(5) : 273-278.
  • 10HUANG WS, METCALF CA, SUNDARAMOORTHI R, et ol. Discovery of 3 - [2 - (imidazo[ 1,2- b]pyridazin - 3 - yl ) ethynyl] - 4 - methyl - N - {4 - [(4 - methylpiperazin - 1 - y 1)methyl] - 3 - (trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR- ABL) kinase including the T315I gatekeeper mutant[J]. J Med Chem, 2010, 53(12): 4701-4719.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部